MIRA 1a
Alternative Names: MIRA-1aLatest Information Update: 06 Dec 2023
At a glance
- Originator MIRA Pharmaceuticals
- Class Analgesics; Anxiolytics; Cannabinoids; Nootropics
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anxiety disorders; Cognition disorders; Neuropathic pain
Most Recent Events
- 04 Dec 2023 Pharmacodynamics data from a preclinical study in Anxiety disorders and Cognition disorders released by MIRA Pharmaceuticals
- 07 Sep 2023 MIRA pharmaceuticals has patent protection for MIRA 1a, prior to September 2023 (MIRA Pharmaceuticals pipeline, September 2023)
- 07 Sep 2023 MIRA Pharmaceuticals plans to file an IND application for Neuropathic pain in Q3 2025 (MIRA Pharmaceuticals pipeline, September 2023)